- Home
- AIAI vs CGEM Comparison
AIAI vs CGEM Comparison
Compare AIAI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIAI | CGEM |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.4M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIAI | CGEM |
|---|---|---|
| Price | $0.95 | $10.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.70 |
| AVG Volume (30 Days) | 459.0K | ★ 799.9K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.84 | $8.23 |
| 52 Week High | $18.88 | $23.19 |
Technical Indicators
Market Signals| Indicator | AIAI | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 29.55 | 30.33 |
| Support Level | $0.84 | N/A |
| Resistance Level | $4.29 | $16.31 |
| Average True Range (ATR) | 0.25 | 1.25 |
| MACD | 0.03 | -0.29 |
| Stochastic Oscillator | 9.59 | 6.04 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.